Maze Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Maze Therapeutics Inc. announced its financial results for the second quarter of 2026, highlighting progress in its MZE829 and MZE782 clinical programs and a strong cash position.
NASDAQ
Maze Therapeutics, Inc. announced its first quarter 2026 financial results, highlighting progress in its clinical-stage drug development programs and a strong cash position.
NASDAQ
Maze Therapeutics reported a net loss of $30.1 million for Q3 2025, with increased R&D expenses, but maintains a strong cash position of $383.9 million following recent capital raises.
NASDAQ
Maze Therapeutics reported a net loss of $33.7 million for Q2 2025, driven by increased R&D expenses for its lead clinical programs and the absence of 2024's one-time licensing revenue.
NASDAQ
10-Q: Maze Therapeutics Reports First Quarter 2025 Financial Results, Highlights Clinical Program Progress
Maze Therapeutics reports a net loss of $32.8 million for Q1 2025, focusing on advancing its clinical programs MZE829 and MZE782.